Key Highlights

  • Second-quarter Revenue of $131 million missed the $131.9 million estimate by 0.56 percent, while adjusted EPS of $0.11 missed the $0.12 estimate by 8.33 percent.
  • The board named Shiv Ramji Chief Executive Officer effective immediately, succeeding Thomas Hogan, who will continue supporting the company as an advisor.
  • Full-year 2026 ARR guidance was lowered to $550 million to $560 million, a $15 million reduction at the midpoint, while adjusted EBITDA guidance was raised to $153 million to $159 million.
  • Annual Recurring Revenue grew 21 percent year over year to $508 million, missing the low end of prior guidance, with the shortfall concentrated in a limited number of large government transactions delayed by new procurement requirements.

Leadership Change Accompanies a Guidance Reset

Cellebrite DI Ltd (NASDAQ:CLBT), a digital forensics and investigative intelligence software provider serving law enforcement and government customers, named Shiv Ramji as Chief Executive Officer effective immediately, succeeding Thomas Hogan, who becomes an advisor to the company. The board characterized the move as an accelerated version of a previously planned succession, citing the need for a product-centric leader focused on cloud and AI architecture as the company's largest strategic opportunity.

The Leadership transition coincided with a disappointing quarter on annual recurring revenue, which grew 21 percent year over year to $508 million but landed below the low end of prior guidance. New CEO Ramji directly acknowledged the shortfall, saying the company did not deliver the performance it expected and attributing the gap primarily to a small number of large government transactions that slipped beyond anticipated timelines rather than any broader loss of customer demand.

Procurement Delays and Slower Pricing Uplift Drive the Guidance Cut

Management said several large deals with U.S. federal and European government customers encountered new administrative and procurement requirements tied to the company's foreign entity status as those customers increasingly sought cloud and AI-enabled solutions rather than traditional on-premise deployments. One notable example involved a customer discovering a previously unrecognized foreign entity permit requirement that delayed a deal by four to five weeks, though the company said it has since secured a master permit expected to expedite future departmental approvals.

A second contributor was slower-than-expected pricing uplift from customers converting to the company's Inseyets digital forensic platform, which reached nearly 65 percent of the installed base by quarter-end, with the gap most pronounced in the U.S. state and local government segment, where growth slowed to just below 20 percent from a mid-20 percent pace a year earlier. Full-year ARR guidance was lowered to $550 million to $560 million, with management now assuming second-half net new ARR roughly in line with the prior year rather than the meaningful acceleration previously anticipated.

New AI Products Show Early Momentum Despite the Broader Shortfall

Newer offerings provided a bright spot within an otherwise disappointing quarter, with Genesis, the company's consumption-based generative AI investigation product launched in mid-June, generating roughly $400,000 in ARR in its first weeks on the market and continuing to add customers into the third quarter across international policing, state attorneys general, and enterprise use cases. The company also secured its first major FedRAMP-certified deal for its Guardian product with a longstanding U.S. federal customer, an initial order management said was nearly 35 times the average annual spend of a typical state or local government agency on the same product.

Defense and intelligence ARR grew 25 percent in the quarter, an area management said saw comparatively less procurement-related delay than the civilian federal segment, while growth products in aggregate contributed 25 percent of the quarter's sequential ARR increase, up from 18 percent the prior quarter. Gross revenue retention continued climbing during the first half, including several points of improvement specifically within the Inseyets customer base, which management pointed to as evidence that customer stickiness remains intact even as near-term pricing capture has moderated.

Management Frames the Reset as an Execution Issue, Not a Demand Problem

Cellebrite's updated guidance implies 14 to 16 percent full-year ARR growth, down from prior expectations, with management attributing roughly half the reduction to slower Inseyets pricing uplift and the remainder to greater conservatism around the timing of large, complex government transactions involving cloud and AI capabilities. The company simultaneously raised full-year adjusted EBITDA guidance to $153 million to $159 million, reflecting continued cost discipline even as top-line expectations came down, and reiterated confidence in reaching 3 percent free Cash Flow margins for the year. Whether the company can restore its prior growth trajectory will likely depend on how quickly newly implemented sales forecasting and deal-qualification discipline improves visibility into large government transactions, and whether Genesis and other AI-native products can scale enough to offset the moderating pricing benefit from the maturing Inseyets conversion cycle.